Wang AJ(1), Wang J(1), Zheng XL(2), Liao WD(1), Yu HQ(3), Gong Y(1), Gan N(1), You Y(1), Guo GH(1), Xie BS(1), Zhong JW(1), Hong JB(1), Liu L(1), Shu X(1), Zhu Y(1), Li BM(1), Zhu X(1). Author information:
(1)Department of Gastroenterology and Hepatology, The First Affiliated Hospital
of Nanchang University, Nanchang, Jiangxi Province, China.
(2)Department of Pharmacy, The First Affiliated Hospital of Nanchang University,
Nanchang, Jiangxi Province, China.
(3)Department of Health Statistics, School of Public Health, Nanchang
University, Nanchang, Jiangxi Province, China.
OBJECTIVES: To investigate whether second-look endoscopy (SLE)-guided therapy could be used to prevent post-endoscopic variceal ligation (EVL) early bleeding.
METHODS: Consecutive cirrhotic patients with large esophageal varices (EV) receiving successful EVL for acute variceal bleeding (AVB) or secondary prophylaxis were enrolled. The patients were randomized into a SLE group and a non-SLE group (NSLE) 10 days after EVL. Additional endoscopic interventions as well as proton pump inhibitors and octreotide administration were applied based on the SLE findings. The post-EVL early rebleeding and mortality rates were compared between the two groups.
RESULTS: A total of 252 patients were included in the final analysis. Post-EVL early rebleeding (13.5% vs 4.8%, P = 0.016) and bleeding-caused mortality (4.8% vs 0%, P = 0.013) were more frequently observed in the NSLE group than in the SLE group. However, post-EVL early rebleeding and mortality rates were reduced by SLE in patients receiving EVL for AVB only but not in those receiving secondary prophylaxis. Patients with Child-Pugh classification B to C at randomization (hazard ratio [HR] 8.77, P = 0.034), AVB at index EVL (HR 3.62, P = 0.003), discontinuation of non-selective β-blocker after randomization (HR 4.68, P = 0.001) and non-SLE (HR 2.63, P = 0.046) were more likely to have post-EVL early rebleeding. No serious adverse events occurred during SLE.
CONCLUSION: SLE-guided therapy reduces post-EVL early rebleeding and mortality rates in cirrhotic patients with large EV receiving EVL for AVB.
Having over 250 Research scholars worldwide and more than 400 articles online with open access.